This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.
We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.
When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment?
Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. Nasdaq:… Read More.
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. RYAH Group Inc.
The study’s data showed that “Cannabis significantly reduced ratings of depression, anxiety, and stress.” Participants in the study recorded their personal experience when using cannabis for their depression and other mental conditions such as anxiety and stress; scientists were able to use data collected from the app to analyze the results.
The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.
The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide J anssen Pharmaceuticals, a subsidiary of Johnson and Johnson (NYSE: JNJ ), data protection for Spravato, a ketamine analog approved for depression. What Is Data Protection And Why Is It Important? and Canada. What Happened?
In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.
SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism.
Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .
.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Patients who met eligibility criteria were able to continue ganaxolone treatment during a 24-week extension to the trial.
AI tools are gaining popularity in biomedical research because while it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, using AI could vastly accelerate the drug-development process. AI automation opens up the possibility of faster, cheaper pharmaceuticals.
Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. CONVENTIONAL TREATMENT. One of the goals of treating epilepsy is to allow people to continue to live functional and fulfilling life’s epilepsy treatment. CANNABIS AS A POTENTIAL TREATMENT.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc. Rex Merchant.
The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.
–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS The median major motor seizure frequency reduction from baseline in the OLE was 30.1%
Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE:
Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied. and migraine severity by 49.6%.
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin. Utilizing this advanced technology, we have effectively produced an extensive base of preclinical, in vitro data that supports and expands our named drug pipeline. October 27, 2021. DENVER, Oct. DENVER, Oct.
Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Talk to a medical cannabis doctor to determine a good treatment plan for your symptoms. The post Is Cannabis Good for Bipolar Disorder?
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.
. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.
In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. THC VS. CBD. Find Out if You Qualify. Get Started. Join 46K+ Subscribers!
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.
By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.
The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. billion in the next six years.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. doi: 10.1016/j.bjoms.2021.06.005.
The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. In other cases, CBDA products — or a mixture of CBD and CBDA — may be preferable, if for instance treatments with high doses of CBD have been unsuccessful for you.
NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,
The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized.
In adults with chronic pain , what are the harms of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the benefits of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the harms of cannabinoids? A Statement from the AHRQ.
You’re probably here because you’re wondering if medical marijuana could help you combat your anxiety and help you stop relying on pharmaceuticals – and according to peer-reviewed research , it probably can! There is a lot of debate over whether pharmaceutical medications are even really helping people with anxiety disorders and depression.
The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.
Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Additionally, there were several instances in which cepharanthine displayed growth inhibition which was comparable or superior to current gold standard treatments, including colorectal, liver and skin cancers.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.
The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.
SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
According to a new study published in the Journal of Pharmacy & Pharmaceutical Sciences, using marijuana as an adjunct treatment for Huntington disease (HD) is both effective and safe. Study selection, quality assessment and data extraction was performed by three reviewers.
drug regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. It’s a non-psychoactive compound found in marijuana and hemp plants and used for treatment of certain medical problems. It’s not just the U.S.
This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. The report authors noted that THC, on the other hand, is touted as a popular option for alleviating the negative effects of AIDS and cancer treatment.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content